fostamatinib (Tavlesse)

following a full submission considered under the orphan equivalent process:

fostamatinib (Tavlesse®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

SMC restriction: for the treatment of patients with severe symptomatic ITP or with a high risk of bleeding who have not had a suitable response to other therapies, including a thrombopoietin receptor‐agonist (TPO-RA), or where use of a TPO-RA is not appropriate.

Fostamatinib has been shown to be significantly more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously-treated patients with ITP.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.